immune thrombocytopenic purpura itp also known idiopathic thrombocytopenic purpura immune thrombocytopenia type thrombocytopenic purpura characterized low platelet count absence causes accompanied redpurple rash called leads increased risk itp manifests two distinct clinical syndromes acute form observed children chronic conditions observed adults acute form often follows infection typically resolves within two months chronic immune thrombocytopenia persists longer six months specific cause unknown itp considered autoimmune disease antibodies several platelet surface structures antigens detected diagnosis itp involves identifying low platelet count complete blood count common blood test however since diagnosis relies excluding potential causes low platelet count additional investigations bone marrow biopsy may necessary certain cases mild cases careful observation may sufficient however instances low platelet counts significant bleeding treatment options may include corticosteroids intravenous immunoglobulin antid immunoglobulin immunosuppressive medications refractory itp respond conventional treatment shows constant relapse splenectomy requires treatment reduce risk significant platelet transfusions may used severe cases extremely low platelet counts individuals experiencing bleeding cases body may compensate producing abnormally large platelets signs itp include spontaneous formation bruises purpura petechiae tiny bruises especially extremities additionally bleeding nostrils andor gums well menorrhagia excessive menstrual bleeding may occur platelet count falls per platelet count per μl lead spontaneous formation hematomas blood masses mouth mucous membranes furthermore bleeding time minor lacerations abrasions usually prolongedcitation needed cases platelet counts drop extremely low levels per μl serious potentially fatal complications may arise complications include subarachnoid intracerebral hemorrhage bleeding inside skull brain lower gastrointestinal bleeding internal bleeding person itp extremely low platelet count susceptible internal bleeding resulting blunt abdominal trauma motor vehicle crash complications unlikely occur platelet count less per petechiae lower extremities oral petechiaepurpura lower lip petechia tongue person platelets due itp petechia lower leg person platelets due itp approximately percent cases antibodies platelets often antibodies platelet membrane glycoproteins iibiiia ibix immunoglobulin g igg type experiment established immune pathogenesis coating platelets igg renders susceptible opsonization phagocytosis splenic macrophages well kupffer cells liver igg autoantibodies also thought damage megakaryocytes precursor cells platelets although believed contribute slightly decrease platelet numbers recent research indicates impaired production glycoprotein hormone thrombopoietin stimulant platelet production may contributing factor reduction circulating platelets observation led development class itptargeted medications referred thrombopoietin receptor stimulus autoantibody production itp probably abnormal cell preliminary findings suggest cells influenced medications target b cells diagnosis itp process exclusion first determined blood abnormalities low platelet count physical signs bleeding secondary causes percent suspected itp cases excluded secondary causes include leukemia medications eg quinine heparin lupus erythematosus cirrhosis hiv hepatitis c congenital causes antiphospholipid syndrome von willebrand factor deficiency onyalai patients presumed itp tested hiv hepatitis c virus platelet counts may corrected treating underlying disease approximately percent cases autoimmune hemolytic anemia itp coexist condition referred evans despite destruction platelets splenic macrophages spleen normally enlarged fact enlarged spleen lead search possible causes thrombocytopenia bleeding time usually prolonged itp patients however use bleeding time diagnosis discouraged american society hematology practice normal bleeding time exclude platelet bone marrow examination may performed patients age respond treatment diagnosis examination marrow increase production megakaryocytes may observed may help establishing diagnosis itp analysis antiplatelet antibodies matter clinicians preference disagreement whether percent specificity test sufficient clinically rare exceptions usually need treat based platelet counts many older recommendations suggested certain platelet count threshold usually somewhere indication hospitalization treatment current guidelines recommend treatment cases significant bleeding treatment recommendations sometimes differ adult pediatric initial treatment usually consists administration corticosteroids group medications suppress immune system dose mode administration determined platelet count whether active bleeding urgent situations infusions dexamethasone methylprednisolone may used oral prednisone prednisolone may suffice less severe cases platelet count improved dose steroid gradually reduced possibility relapse monitored percent experience relapse dose reduction longterm steroids avoided possible potential sideeffects include osteoporosis diabetes another option suitable rhpositive patients functional spleens intravenous administration rhod immune globulin human antid mechanism action antid fully understood however following administration antidcoated red blood cell complexes saturate fcγ receptor sites macrophages resulting preferential destruction red blood cells rbcs therefore sparing antibodycoated platelets two antid products indicated use patients itp winrho sdf rhophylac common adverse reactions headache nauseavomiting chills fever needed increasing use immunosuppressants mycophenolate mofetil azathioprine effectiveness chronic refractory cases immune pathogenesis offlabel use vinca chemotherapy agent vincristine may however vincristine significant side use treating itp must approached caution especially children intravenous immunoglobulin ivig may infused cases order decrease rate macrophages consume antibodytagged platelets however sometimes effective costly produces improvement generally lasts less month nevertheless case itp patient already scheduled surgery dangerously low platelet count experienced poor response treatments ivig rapidly increase platelet counts also help reduce risk major bleeding transiently increasing platelet thrombopoietin receptor agonists pharmaceutical agents stimulate platelet production bone marrow differ previously discussed agents act attempting curtail platelet two products currently available thrombopoietin receptor agonists exhibited greatest success far treating patients refractory side effects thrombopoietin receptor agonists include headache joint muscle pain dizziness nausea vomiting increased risk blood splenectomy removal spleen may considered patients either unresponsive steroid treatment frequent relapses tapered steroids months platelets bound antibodies taken macrophages spleen fc receptors removal spleen reduces platelet destruction procedure potentially risky itp cases due increased possibility significant bleeding surgery durable remission following splenectomy achieved percent itp even though consensus regarding shortterm efficacy splenectomy findings longterm efficacy sideeffects splenectomy percent itp cases relapsed percent itp cases response use splenectomy treat itp diminished since development steroid therapy pharmaceutical platelet transfusion alone normally recommended except emergency usually unsuccessful producing longterm platelet count increase underlying autoimmune mechanism destroying patients platelets also destroy donor platelets platelet transfusions considered longterm treatment adults particularly living areas high prevalence helicobacter pylori normally inhabits stomach wall associated peptic ulcers identification treatment infection shown improve platelet counts third patients fifth platelet count normalized completely response rate similar found treatment rituximab expensive less children approach supported evidence except high prevalence areas urea breath testing stool antigen testing perform better serologybased tests moreover serology may falsepositive treatment general patients acute itp rarely lifethreatening patients ultimately stable lower platelet counts hemostatic person unlike pediatric patients cured adults run chronic course even normal platelet count considered range per microlitre μl blood healthy individuals hence one may considered thrombocytopenic range although threshold diagnosis itp tied specific incidence itp estimated new cases per million per year children accounting half number least percent childhood cases end remission within six months even without moreover third remaining chronic cases usually remit followup observation another third end mild thrombocytopenia defined platelet count number immune related genes polymorphisms identified influencing predisposition itp allele increasing susceptibility shown itp usually chronic probability durable remission male female ratio adult group varies age ranges childhood cases roughly equal sexes median age adults diagnosis ratio male female adult cases tends widen age united states adult chronic population thought approximately women outnumbering men approximately resulted itp designated orphan mortality rate due chronic itp varies tends higher relative general population age range study conducted great britain noted itp causes approximately percent higher rate mortality compared sex agematched subjects without itp increased risk death itp largely concentrated middleaged elderly ninetysix percent reported itprelated deaths individuals years older significant difference noted rate survival males incidence itp pregnancy well known may occur trimester pregnancy common cause significant thrombocytopenia platelets less second trimester common cause significant thrombocytopenia first third nonpregnant individuals itp pregnancy diagnosis exclusion potential causes low platelets pregnancy require consideration include obstetrical causes preeclampsia hellp syndrome hemolysis elevated liver enzymes low platelets thrombotic microangiopathies may occur causes thrombocytopenia may occur pregnancy drug induced thrombocytopenia hereditary thrombocytopenia pseudothrombocytopenia also ruled itp difficult distinguish gestational thrombocytopenia far common cause thrombocytopenia pregnancy unlike itp platelet count gestational thrombocytopenia rarely goes platelet count even rare seen less cases gestational thrombocytopenia also unlike itp gestational thrombocytopenia cause neonatal maternal bleeding neonatal women itp often decrease platelet counts become pregnant often requiring pregnant women itp times likely bleeding episodes pregnancy compared nonpregnant females itp however proper treatment platelets rarely drop itp severe bleeding rare occurrence treatment maternal deaths due itp extremely itp found increase risk common obstetrical complications increased risk preeclampsia premature delivery placental abruption blood clots observed itp platelet counts usually return prepregnancy levels antiplatelet autoantibodies pregnant woman itp attack patients platelets also cross placenta react fetal platelets leading thrombocytopenia thrombopoietin levels also increased pregnancy thought due placental production estradiol estradiol leads decreased megakaryocyte activity therefore decreased platelet therefore itp significant cause fetal neonatal immune thrombocytopenia approximately newborns affected itp platelet counts risk intracerebral hemorrhage comparable infants neonatal alloimmune thrombocytopenia lab test reliably predict neonatal thrombocytopenia occur risk neonatal thrombocytopenia increased recommended pregnant women thrombocytopenia previous diagnosis itp tested serum antiplatelet antibodies indications treatment pregnant people itp include presence bleeding platelet counts less planned procedures amniocentesis raising platelet levels prior delivery minimum platelet level vaginal delivery cesarean section rarely platelet transfusion may needed facilitate safe first line therapies itp include steroids prednisone ivig second line therapies usually used first line therapies fail thrombocytopenia persists include rituximab thrombopoetin receptor agonsists romiplostim platelet transfusions may performed newborns depending degree thrombocytopenia ivig steroids methylprednisolone may also given raise platelet recommended neonates followed serial platelet counts first days ultrasound mri also recommended severely thrombocytopenic infants rule brain initial reports portuguese physician amato lusitano lazarus de la rivière physician king france german physician poet paul gottlieb werlhof wrote complete initial report purpura itp platelets unknown name werlhofs disease used widely current descriptive name became platelets described early century several investigators linked purpura abnormalities platelet first report successful therapy itp young polish medical student paul kaznelson described female patients response splenectomy remained firstline remedy introduction steroid therapy httpsenwikipediaorgwikiautoimmunethrombocytopenicpurpura